Tianjin Institute of Pharmaceutical Research Co., Ltd
2 clinical trials · Sponsor
◉ Watch Tianjin Institute of Pharmaceutical Research Co., Ltd
| Record | Firm | Date |
|---|---|---|
| Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE). (NCT06601127) | Tianjin Institute of Pharmaceutical Research Co., Ltd | 2025-02-21 |
| Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects (NCT06584812) | Tianjin Institute of Pharmaceutical Research Co., Ltd | 2024-09-09 |
Track Tianjin Institute of Pharmaceutical Research Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.